Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28081914

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Feb
First author
Plimack ER

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Feb;18(2):160-161. doi: 10.1016/S1470-2045(16)30675-1.
    note
    Source null
    related pmid
    28081913
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2017 Mar;14(3):133. doi: 10.1038/nrurol.2017.12.
    note
    Source null
    related pmid
    28117845
    relationship
    Comment in

Authors and identifiers

  1. name
    Plimack ER
    type
    Author
  2. name
    Bellmunt J
    type
    Author
  3. name
    Gupta S
    type
    Author
  4. name
    Berger R
    type
    Author
  5. name
    Chow LQ
    type
    Author
  6. name
    Juco J
    type
    Author
  7. name
    Lunceford J
    type
    Author
  8. name
    Saraf S
    type
    Author
  9. name
    Perini RF
    type
    Author
  10. name
    O'Donnell PH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Plimack ER
    type
    Author
  2. name
    Bellmunt J
    type
    Author
  3. name
    Gupta S
    type
    Author
  4. name
    Berger R
    type
    Author
  5. name
    Chow LQ
    type
    Author
  6. name
    Juco J
    type
    Author
  7. name
    Lunceford J
    type
    Author
  8. name
    Saraf S
    type
    Author
  9. name
    Perini RF
    type
    Author
  10. name
    O'Donnell PH
    type
    Author
bibliography ids
  1. nci-bib-4dec3709ca1c49b2ccb22e87
book metadata
content sha256
7fee1066029d74dad5ba06e637f1d2af864afeeef90453ae6957f935886121cd
document type
citation
dois
  1. 10.1016/S1470-2045(17)30007-4
electronic publication date
display
2017 Jan 10
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28081914
immutable id
pubmed:28081914@7fee1066029d74dad5ba06e637f1d2af864afeeef90453ae6957f935886121cd
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
212-220
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Feb;18(2):160-161. doi: 10.1016/S1470-2045(16)30675-1.
    note
    Source null
    related pmid
    28081913
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2017 Mar;14(3):133. doi: 10.1038/nrurol.2017.12.
    note
    Source null
    related pmid
    28117845
    relationship
    Comment in
outcomes validated
false
pmid
28081914
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
6525685869d7496001261e84948fc8250b662724d6abee696fd8a63ff498e92b
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Feb
precision
month
year
2017
publication types
  1. Clinical Trial, Phase I
  2. Journal Article
  3. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28081914/
title
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

Preserved source evidence · Not medical advice